Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Lu AG22515 (APB-A1) in Healthy Adults
NCT05136053Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Mar 2022
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AG22515 in thyroid eye disease (TED) and multiple sclerosis (MS) (6 arms), sponsored by Lundbeck. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Mar 2022; status: completed.
02
Drugs
Lu AG22515
03
Conditions
thyroid eye disease (TED)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05136053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136053.